Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice.

ABSTRACT:

Background

High-grade serous ovarian cancer is a lethal gynecologic disease. Conventional therapies, such as platinum-based chemotherapy, are rendered inadequate for disease management as most advanced disease patients develop resistance to this therapy and soon relapse, leading to poor prognosis. Novel immunotherapy and targeted therapy are currently under investigation as treatment options for ovarian cancer, but so far with little success. Epigenetic changes, such as aberrant DNA methylation, have been reported in resistance to platinum-based therapy. Decitabine is a hypomethylating agent which is effective against platinum-resistant disease and also exhibits several anti-tumor immune functions. Selinexor is a selective inhibitor of nuclear protein export. It restored platinum s

SUBMITTER: Stiff PJ 

PROVIDER: S-EPMC10526280 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature